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ABSTRACT
Aromatase inhibitors (a i s) are commonly used as 
adjuvant treatment in postmenopausal women with 
hormone receptor–positive early breast cancer. 
With both steroidal and nonsteroidal a i s, a i -induced 
arthralgia is frequently observed. The mechanism 
of a i -induced arthralgia remains unknown, and 
the data available from clinical trails using a i s are 
limited. We review the pertinent information from a 
clinical perspective, including an algorithm to treat 
a i -induced arthralgia.
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1.  INTRODUCTION
Arthralgia is a symptom commonly seen in patients 
treated with any aromatase inhibitor (a i ). Trials 
with a i s have used various terms to describe joint 
discomfort. Table i summarizes the incidence of that 
symptom in various clinical trials.
2.  RISK FACTORS
Although no known risk factors (see Table ii) uni-
formly emerged in the trials with a i s, patients treated 
with adjuvant chemotherapy in the a t a c  (Arimidex 
Alone or in Combination with Tamoxifen) trial had 
a somewhat higher incidence and earlier onset of 
arthralgia 6,7. Increasing use of granulocyte colony–
stimulating factor (g-c s f) and taxane chemotherapies 8 
in the adjuvant setting are seen as additional risk 
factors. In the a t a c  trial, previous arthritis or arthralgia 
symptoms were seen in 46% of patients who devel-
oped arthralgia after initiation of anastrozole therapy. 
Among those patients, a relatively younger age group 
had a higher incidence of joint symptoms 6,7.
3.  CLINICAL DESCRIPTION
Patients usually present with morning stiffness and 
joint discomfort in various sites, including hands, 
knees, back, hips, and shoulders. The clinical ex-
amination should pay particular attention to the af-
fected joints and periarticular structures. Any signs of 
inflammation—such as tenderness, warmth, swelling, 
or erythema—should be noted. In our experience, no 
particularly consistent abnormality affiliated with 
the use of a i s is observed on joint examination. No 
tests specifically address the diagnosis of a i -induced 
arthralgia. Plain radiographs and other related tests 
can be used to rule out other causes of arthralgia. The 
differential diagnosis should include bone disease, 
osteoarthritis, rheumatoid arthritis, and periarticular 
pathologies, among other possibilities.
Arthralgia has been observed to begin appearing at 
approximately 2 months after the start of treatment and 
to peak at around the 6-month mark, but it can appear 
up to 2 years after initiation of therapy 6. In the a t a c  
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t a b l e  i  Incidence of arthralgia in aromatase inhibitor trials
Reference Trial
short name
Arthralgia incidence (%) with
Anastrozole   Tamoxifen Letrozole Exemestane
Fallowfield et al., 2004 1 a t a c 35.9   29.8
Thürlimann et al., 2005 2 b i g  1-98   13.5 20
Coombes et al., 2004 3 i e s   11.8 18.6
Jakesz et al., 2005 4 a r n o  95 16.8  8
Whelan et al., 2005 5 m a .17 25   2188
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trial, the intensity of discomfort was rated between 
mild and moderate in 92% of patients 6. Users of 
anastrozole and tamoxifen both experienced a similar 
incidence (about 10%) of disabling events related to 
such joint symptoms. In a t a c , the withdrawal rate be-
cause of arthralgia was quoted as only 2.1% in patients 
treated with anastrozole, but other investigators have 
reported a higher incidence. In the report by Presant et 
al. 9, 20% of patients discontinued an a i  because of the 
severity of arthralgia. On average, their pain intensity 
was rated as 7.5 out of 10. Crew et al. 10 reported that, 
of 200 patients treated with a i s, 47% reported joint 
symptoms. In that survey, patients who had a higher 
body mass index (25–30 m2/kg2) and those who had 
been previously treated with tamoxifen were less 
likely to experience joint symptoms when treated with 
an a i . Patients previously treated with taxanes were 
four times more likely to develop arthralgia.
The resolution of arthralgias in various trials 
appears to begin around the 6-month mark from 
the onset of therapy, improving in at least 50% of 
patients 6. By 18 months, 75% of the patients in the 
a t a c  trial had experienced significant amelioration of 
their symptoms 6,7.
4.  POTENTIAL MECHANISMS BEHIND  
AI-INDUCED ARTHRALGIA
The acute drop in estrogen produced by aromatase 
inhibition is the most likely underlying mechanism 
for joint symptoms. That hypothesis is supported 
by the observation that backaches, joint pains, and 
stiffness are commonly experienced among peri- and 
postmenopausal women in the general population 8. 
The development of arthralgia after chemotherapy, 
which also causes hormone suppression, has been 
well documented 10,11.
No structural damage to articular surfaces, liga-
ments, or other joint structures has been documented 
with a i -induced arthralgia (unlike the case with osteoar-
thritis or rheumatoid arthritis). In a small prospective 
study, 12 patients on a i s were followed by question-
naire, examination, and magnetic resonance imaging 
of hands and wrists at baseline and after 6 months. No 
patient had joint symptoms before treatment. After 6 
months, these patients showed enhancement of the 
synovium and an increase in intra-articular and tendon 
sheath fluid, with associated complaints of stiffness in 
the small joints of the wrists and hands 12. That finding 
correlates well with the relative absence of signs of 
arthritis in patients with a i -induced arthralgia.
5.  TREATMENT OPTIONS AND ALGORITHM
Aromatase inhibitor–induced arthralgia is a relatively 
newly recognized entity. It is reasonable to extrapolate 
and draw data from the osteoarthritis and rheumatoid 
arthritis literature for the overall management of joint 
symptoms seen in patients on an a i . But because the 
exact mechanism of the symptoms is unknown, these 
borrowed strategies may or may not work. Therefore 
the algorithm presented here (Figure 1) contains a 
combination of an evidence-based clinical approach 
and our own clinical experience.
Counselling and education appear to be the two 
most important steps in the overall management of 
these patients. It should be emphasized that therapy 
with an a i  is a long-term plan, usually 5 years. More-
over, it has been observed as an emerging trend that 
many treating physicians may elect to continue a i s 
for an even longer duration, depending on the risk of 
recurrence at initial presentation and other factors. 
The side effects should therefore be described clearly 
from beginning. Follow-up should be scheduled at 2 
months and at 6 months from the date of a i  therapy 
initiation. Further follow-up and counselling may 
depend on the individual patient’s symptoms. The 
clinician should emphasize the clear benefit of re-
ducing the risk of breast cancer recurrence and the 
importance of adherence to the long-term use of an 
a i  at each patient visit. Several available options to 
treat a i -induced arthralgia should be discussed with 
patients, depending on the severity of symptoms.
For patients with a i -induced arthralgia, simple 
lifestyle modifications such as weight reduction and 
regular exercise, with increasing joint mobility, may 
help them to regain muscle strength and may improve 
t a b l e  ii  Risk factors for arthralgia
Younger age
Adjuvant chemotherapy (use of taxanes in particular)
Use of granulocyte colony–stimulating factor
Prior history of arthralgia, arthritis, or fibromyalgia
Proposed Management Algorithm for AI Induced Musculoskeletal 
Symptoms in Patients with EBC 
Musculoskeletal symptoms
Baseline program
Life style modification – weight loss, exercise, morning warm ups
Physiotherapy/ occupational therapy/ massage therapy
Mild / moderate pain
< 5 / 10
Moderate/severe pain
> 6/10
Acetaminophen
Ibuprofen
NSAIDS
COX 2 inhibitors
Tramadol (Tramacet)
Tylenol with Codeine
COX 2 inhibitors
NSAIDS 
Opioid combos– Tramacet, 
Percocet and Tylenol # 3
Pain modifiers – TCA’s,
Gabapentin,  Lyrica
Referral to rheumatologist
(May need to consider intra 
– articular steroids )
Drug holiday?
∆ AI or switch 
to Tamoxifen
Complementary Rx: 
Glucosamine, 
Chondroitin
Zeel, Acupuncture, 
Hypnosis etc 
Education and Counselling
Reinforce/education
Reinforce/education
Reinforce/education
f i g u r e  1  Proposed management algorithm for aromatase inhibi-
tor (a i)–induced musculoskeletal symptoms in patients with early 
breast cancer (e b C). n s a i ds = nonsteroidal anti-inflammatory drugs; 
COX2 = cyclooxygenase 2; Δ = change; Rx = prescription; t C a s = 
tricyclic antidepressants.89
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fatigue, posture, and flexibility. Improvement in func-
tion and pain scores in patients with osteoarthritis of 
the knee has been shown in research trials of weight 
loss and exercise, with the combination of the two 
interventions being more effective than either one 
alone. A 10% weight reduction in such patients im-
proved function by almost 30% 13,14. Similar benefits 
were reported in trials of hydrotherapy 15,16.
Massage therapy using the Swedish technique has 
been demonstrated to reduce pain and improve func-
tion for patients with symptomatic osteoarthritis of 
the knee 17. Relaxation techniques, biofeedback, and 
visual imagery can also be helpful 18. A pilot study of 
the effectiveness of guided imagery combined with 
progressive muscle relaxation has shown promise as 
an effective self-management technique for chronic 
pain associated with osteoarthritis 19.
Among non-pharmaceutical interventions, hyp-
nosis remains an under-investigated but potentially 
effective therapy. In clinical practice, a combination 
of hypnosis with other strategies may prove more ef-
fective, particularly in refractory cases. A case report 
on arthralgia and myalgias recently published by 
our group demonstrated the positive effect of adding 
hypnosis 20.
No trials of the foregoing modifications have 
involved patients with a i -induced arthralgia, but it 
may be reasonable to suggest them, based on similar 
symptoms felt by the patients who were studied and 
the improvement observed. Most of the adjuvant a i  
trials incorporated the use of calcium and vitamin D 
supplements. Severe hypovitaminosis D has been 
reported to be prevalent in patients with persistent 
nonspecific musculoskeletal pain and has been postu-
lated as a potential cause of pain in women on a i s 21. 
The use of these two supplements in patients with 
low levels of vitamin D has been shown to improve 
musculoskeletal symptoms 22.
To control the discomfort, acetaminophen alone 
should be tried first. Ibuprofen or other nonsteroidal 
anti-inflammatory drugs can be added for continued 
pain. The addition of opioids with or without acet-
aminophen can be used for more severe or nonrespon-
sive pain. Pain modifiers such as tricyclic antidepres-
sants or anticonvulsants may be added for severe, 
resistant, painful arthralgia. For complex situations 
or puzzling diagnostic issues, a rheumatology or pain 
management consultation is appropriate.
Occasionally, it is difficult to be clinically con-
fident that the arthralgia is associated with a i  use. A 
drug holiday for 2–3 weeks may safely be suggested 
to help resolve this issue.
Many complementary therapies have been tried 
in various arthritic conditions with mixed results. 
Acupuncture and homeopathic preparations have both 
shown some promise in alleviating arthritis pain 23,24. 
In a meta-analysis that considered more than 700 
patients, chondroitin sulphate used in double-blind 
fashion for 2–12 months at doses of 800–2000 mg 
daily was shown to improve osteoarthritic pain. An 
interesting study report by Bruyere et al. 25 random-
ized 319 postmenopausal women to glucosamine or 
placebo and followed them prospectively for 3 years. 
The total knee replacement rate was almost 2.5 times 
higher in the placebo-treated group. Furthermore, 
joint space narrowing, quality of life, pain, and func-
tion related to the joints were better with glucosamine-
supplemented participants.
Recently, two studies examined improvement in 
joint symptoms after patients were switched from one 
nonsteroidal a i  to another. Close to 180 patients who 
were receiving an adjuvant a i  and were complaining 
of joint symptoms were switched to another a i  (anas-
trozole to letrozole, or vice-versa) after 3 months of 
therapy 26. About half these patients experienced im-
provement or resolution of their symptoms after the 
switch. Almost 75% of patients who were switched to 
tamoxifen instead of another a i  obtained relief. In the 
second report 27, 179 patients treated with adjuvant 
anastrozole who had experienced severe joint pain 
were switched to letrozole after a 1-month washout pe-
riod. Two thirds of those patients were able to continue 
with letrozole treatment with improved symptoms. The 
results of the foregoing studies suggest that switching 
to another a i  may be reasonable in difficult and resis-
tant cases. If the arthralgia remains unresolved, a final 
switch to tamoxifen could be considered.
6.  SUMMARY
Arthralgia associated with the use of a i s is a compli-
cated and challenging clinical problem for health care 
personnel. This side effect is common and threatens 
to adversely affect compliance unless managed ap-
propriately. The algorithm presented here offers a 
reasonably comprehensive approach to managing 
this common side effect and attempts to keep patients 
compliant with their potentially life-saving therapy.
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